Christian Jackisch,1 Eva-Maria Grischke,2 Andreas Schneeweiss,3
Poster P5-19-12 Subgroup Analysis of Efficacy in Routine Treatment—Results of the 2nd Interim Analysis of BRAWO, the Non-Interventional Trial “Breast Cancer Treatment With Everolimus and Exemestane for HR+ Women” Christian Jackisch,1 Eva-Maria Grischke,2 Andreas Schneeweiss,3 Thomas Decker,4 Christoph Uleer,5 Frank Förster,6 Oliver Tomé,7 Pauline Wimberger,8 Christian Kurbacher,9 Bettina Mueller,10 Nadia Harbeck,11 Christoph Mundhenke,12 Sherko Kümmel,13 Mathias Muth,14 Julia Kreuzeder,14 Wilhelm Bloch,15 Hans Tesch,16 Diana Lueftner,17 Florian Schütz,3 Peter Fasching18 1Breast Center at the Hospital Offenbach, Offenbach, Germany; 2Department of Obstetrics and Gynecology, University Tuebingen, Tuebingen, Germany; 3Department of Obstetrics and Gynecology, University Heidelberg, Heidelberg, Germany; 4Medical Center Ravensburg, Ravensburg, Germany; 5Medical Center Hildesheim, Hildesheim, Germany; 6Poliklinik GmbH Chemnitz, Chemnitz, Germany; 7Women’s Hospital and School for Midwives, St. Vincentius Clinic, Karlsruhe, Germany; 8Department of Obstetrics and Gynecology, Technical University, Dresden, Dresden, Germany; 9Gynecology and Obstetrics, Medical Center Bonn-Friedensplatz, Bonn, Germany; 10Obstetrics & Gynecology, The GRN Health Centers, Rhein-Neckar, Weinheim, Germany; 11Department of Obstetrics and Gynecology, Hospitals Grosshadern and Maistrasse-Innenstadt, University of Munich, Munich, Germany; 12Department of Obstetrics and Gynecology, University Hospital of Schleswig-Holstein, University of Kiel, Kiel, Germany; 13Interdisciplinary
[Show full text]